SCHEMBL26686243

SCHEMBL26686243

CC(C)(O)c1cc2c(Cl)ccnc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.42
PRKCI P41743 1/20 0.42
KDM5A P29375 1/20 0.41
KDM5B Q9UGL1 1/20 0.41
DAO P14920 1/20 0.40
CDC7 O00311 1/20 0.39
PIM1 P11309 1/20 0.39
CDK9 P50750 1/20 0.39
IKBKB O14920 5/20 0.38
CHUK O15111 5/20 0.38
AURKA O14965 1/20 0.36
AURKB Q96GD4 1/20 0.36
ALK Q9UM73 1/20 0.34
PTK6 Q13882 1/20 0.33
CSNK1D P48730 1/20 0.33
MAPK14 Q16539 1/20 0.33
NUDT1 P36639 3/20 0.33
DYRK1B Q9Y463 1/20 0.33
SMYD3 Q9H7B4 1/20 0.32
GCK P35557 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30633344 1.00 AXL (0.42) AXLPRKCIKDM5AKDM5BDAO
SCHEMBL3413744 0.87 IKBKB (0.45) AXLPRKCIDAOCDC7PIM1
SCHEMBL31420487 0.87 IKBKB (0.45) AXLPRKCIDAOCDC7PIM1
SCHEMBL31420480 0.83 AXL (0.39) AXLPRKCIDAOCDC7PIM1
SCHEMBL26686519 0.83 AXL (0.39) AXLPRKCIDAOCDC7PIM1
SCHEMBL30509532 0.80 IKBKB (0.45) AXLPRKCIDAOCDC7PIM1
SCHEMBL2984796 0.80 IKBKB (0.45) AXLPRKCIDAOCDC7PIM1
SCHEMBL1154194 0.74 AXL (0.48) AXLPRKCIDAOCDC7PIM1
SCHEMBL29487177 0.74 AXL (0.48) AXLPRKCIDAOCDC7PIM1
SCHEMBL26686642 0.73 AXL (0.41) AXLPRKCIDAOCDC7PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 EP disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB AXL 1479/4885PRKCI 32/4885KDM5A 1606/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.